Most people with relapsing MS who were treated with Briumvi for six years did not have confirmed disability progression, a ...
Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...
The CAR T-cell therapy equecabtagene autoleucel, or eque-cel, was shown in trial to improve walking ability for five ...
Patients with MS (114 [87.7%] with RRMS; 16 [12.3%] with SPMS) who discontinued first-line DMT were included in the analysis. Over a median follow-up of 59.5 months, 78 patients who discontinued DMT ...
—Data from this real-world study revealed that patients with MS being treated with DMTs had a disproportionally higher number of cases of herpes zoster compared with patients treated with other ...
Sepsis is an alarmingly common cause behind ICU admissions in patients with multiple sclerosis (MS), a retrospective, population-based cohort study indicates. Furthermore, it contributes to a ...
Discover the groundbreaking medical trial offering new hope for autoimmune diseases and the first courageous patient behind ...
HealthDay on MSN
Early MS Patients Fare Worse If They Eat Junk Food
MS occurs when the immune system starts attacking the protective sheath that covers nerve cells, which is called myelin. This ...
The ALS and MS Walk for Living took place today in Chelsea, drawing around 600 participants to support the Leonard Florence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback